Monitor for any definitive proxy statement or activist response ahead of the annual meeting. The departure of a director near the AGM could signal board refreshment or be related to ongoing governance discussions.
Price Chart
Executive Summary
Jazz Pharmaceuticals filed a DEFA14A, which is additional definitive proxy soliciting material, filed as an amendment or supplement to the proxy statement. The filing appears to be related to the 2026 annual meeting notice, following a recent announcement that director Anne O'Riordan will not stand for re-election. No substantive financial or strategic details are present in the filing documents.
Key Facts
- Filed as DEFA14A (additional definitive proxy soliciting materials)
- Relates to the 2026 annual meeting of shareholders
- Filed 10 days after an 8-K (5.02) disclosing a director will not stand for re-election
- Director Anne O'Riordan's decision was not due to any dispute with the company
Financial Impact
Not specified
Risk Factors
- Potential for proxy fight or activist campaign if further board changes emerge
- Director departure may reduce board diversity or specific expertise
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001232524-26-000030 |
| Document: 0001232524-26-000030-index-headers.html | 0001232524-26-000030 |
| Document: 0001232524-26-000030-index.html | 0001232524-26-000030 |
| Document: 0001232524-26-000030.txt | 0001232524-26-000030 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 6d ago | Press Release | $213.76 $211.97 | ▼ −0.84% | ▼ −1.36% | $210.99 (−1.30%) |
Oct 9, 2026 17d ago | 8-K | $218.42 $216.75 | ▼ −0.76% | ▼ −0.70% | $210.99 (−3.40%) |
Oct 8, 2026 17d ago | 144 | $218.42 $216.75 | ▼ −0.76% | ▼ −0.70% | $210.99 (−3.40%) |
Oct 6, 2026 19d ago | 144 | $231.19 $222.45 | ▼ −3.78% | ▼ −3.36% | $210.99 (−8.74%) |
Oct 1, 2026 24d ago | 144 | $235.67 $236.04 | ▲ +0.16% | ▼ −0.52% | $210.99 (−10.47%) |
Sep 15, 2026 5w ago | 8-K | $240.83 $243.59 | ▲ +1.15% | ▲ +1.59% | $210.99 (−12.39%) |
Sep 14, 2026 5w ago | Insider Cluster | $240.83 $243.59 | ▲ +1.15% | ▲ +1.59% | $210.99 (−12.39%) |
Sep 10, 2026 6w ago | Insider Cluster | $245.80 $245.87 | ▲ +0.03% | ▲ +0.47% | $210.99 (−14.16%) |
Sep 2, 2026 7w ago | Insider Cluster | $247.57 $246.81 | ▲ +0.30% | ▼ −0.08% | $210.99 (+14.78%) |
Aug 31, 2026 7w ago | 144 | $243.71 $245.57 | ▲ +0.76% | ▲ +0.32% | $210.99 (−13.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers